Literature DB >> 17015906

11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.

Andrew G Horti1, Hong Fan, Hiroto Kuwabara, John Hilton, Hayden T Ravert, Daniel P Holt, Mohab Alexander, Anil Kumar, Arman Rahmim, Ursula Scheffel, Dean F Wong, Robert F Dannals.   

Abstract

UNLABELLED: The development of the radioligands for PET imaging of the cerebral cannabinoid receptor (CB1) is of great importance for studying its role in neuropsychiatric disorders, obesity, and drug dependence. None of the currently available radioligands for CB1 are suitable for quantitative PET, primarily because of their insufficient binding potential (BP) in brain or low penetration through the blood-brain barrier (BBB). The goal of this study was to evaluate 11C-JHU75528, an analog of the selective CB1 antagonist rimonabant, in vivo as a potential CB1 radioligand for PET.
METHODS: The brain regional distribution and pharmacology of 11C-JHU75528 have been evaluated in vivo in mice (dissection) and baboons (PET).
RESULTS: 11C-JHU75528 readily entered the mouse and baboon brain and specifically and selectively labeled cerebral CB1 receptors. The ratio of striatum to brain stem in mice and the binding potential (BP) in the baboon putamen were 3.4 and 1.3-1.5, respectively. The specific binding of 11C-JHU75528 in vivo was blocked by preinjection of nonlabeled JHU75528. Administration of rimonabant (1 mg/kg, intravenously) also blocked the specific binding of 11C-JHU75528 in the mouse and baboon brain, whereas various central noncannabinoid drugs did not significantly reduce the 11C-JHU75528 binding in the mouse brain. 11C-JHU75528 formed several hydrophilic metabolites, but only a minute fraction of metabolic radioactivity penetrated the BBB.
CONCLUSION: 11C-JHU75528 holds promise as a radiotracer with suitable imaging properties for quantification of CB1 receptors in the human brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17015906

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  46 in total

1.  Centrally mediated antinociceptive effects of cannabinoid receptor ligands in rat models of nociception.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Pharmacol Biochem Behav       Date:  2011-09-17       Impact factor: 3.533

2.  Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences.

Authors:  Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

Review 3.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

4.  Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT.

Authors:  Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-13       Impact factor: 9.236

5.  Activation of spinal and supraspinal cannabinoid-1 receptors leads to antinociception in a rat model of neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Brain Res       Date:  2011-07-26       Impact factor: 3.252

6.  Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.

Authors:  Sean R Donohue; Joseph H Krushinski; Victor W Pike; Eyassu Chernet; Lee Phebus; Amy K Chesterfield; Christian C Felder; Christer Halldin; John M Schaus
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

7.  Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinity.

Authors:  Hong Fan; Evangelia Kotsikorou; Alexander F Hoffman; Hayden T Ravert; Daniel Holt; Dow P Hurst; Carl R Lupica; Patricia H Reggio; Robert F Dannals; Andrew G Horti
Journal:  Eur J Med Chem       Date:  2008-04-18       Impact factor: 6.514

Review 8.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 9.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

10.  Development and characterization of a promising fluorine-18 labelled radiopharmaceutical for in vivo imaging of fatty acid amide hydrolase.

Authors:  Oleg Sadovski; Justin W Hicks; Jun Parkes; Roger Raymond; José Nobrega; Sylvain Houle; Mariateresa Cipriano; Christopher J Fowler; Neil Vasdev; Alan A Wilson
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.